CRO Genomics version 1.0

  • Research type

    Research Study

  • Full title

    Genomic Investigation of Carbapenem Resistant Organisms Isolated Within NHS Lothian

  • IRAS ID

    368985

  • Contact name

    Kate Templeton

  • Contact email

    kate.templeton@nhs.scot

  • Sponsor organisation

    University of Edinburgh

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    1 years, 11 months, 31 days

  • Research summary

    Carbapenems are very strong antibiotics that doctors usually save for when other treatments don’t work. They are used to treat serious infections caused by bacteria that are resistant to many common drugs. Recently, more bacteria have become resistant even to these powerful antibiotics, which is a growing public health concern. Antibiotic resistant bacterial infections are especially serious in hospitals, where they are linked to higher death rates and increased pressure on healthcare services.

    Cases of carbapenem resistant bacteria are rising around the world and in Scotland. In 2024, there were 42% more cases in Scotland than the year before, continuing a strong upward trend over the past five years. It is important to understand what is driving these increases, if current risk-based screening is identifying all cases or patient factors and transmission patterns linked to resistance are changing.

    Whole genome sequencing (WGS) is a laboratory method that reads all the genetic material of a bacterium. This helps scientists identify exactly what type of bacteria it is, what resistance genes it has, and how it might be spreading between patients or healthcare settings.

    This study will use WGS to look at carbapenem resistant bacteria from patients in NHS Lothian between April 2024 and March 2026. By combining genetic information with patient data, the aim is to better understand how these bacteria spread and to improve infection control and patient care.

  • REC name

    North West - Preston Research Ethics Committee

  • REC reference

    26/NW/0240

  • Date of REC Opinion

    4 Aug 2026

  • REC opinion

    Favourable Opinion